Literature DB >> 20589884

Mosaic expression of Med12 in female mice leads to exencephaly, spina bifida, and craniorachischisis.

Pedro P Rocha1, Wilfrid Bleiss, Heinrich Schrewe.   

Abstract

BACKGROUND: A precise temporal and spatial regulation of gene expression is necessary to achieve neural tube closure. Med12, a subunit of the mediator complex, can bind transcription factors and modulate expression of their target genes. Med12 is essential during early mouse development and is important for neural tube closure.
METHODS: We have made use of a mouse line carrying a conditional null allele of the X-linked Med12 gene to generate heterozygous female embryos that express Med12 in a mosaic fashion thus allowing the study of the role of Med12 during neural tube closure.
RESULTS: Mosaic expression of Med12 causes a wide variety of embryonic phenotypes. Some embryos were unable to complete turning and were found with arrested development at embryonic day (ED) 9.5. Others were able to pass ED 12.5 and displayed defects in neural tube closure. These defects included exencephaly, spina bifida, craniorachischisis, split face, and curly tail. Histologic and skeletal analyses of these mutant females show that the neural plate is unable to elevate and is completely flat in the regions of the body axis where neural tube closure fails.
CONCLUSIONS: We report examples of all known neural tube defects implying Med12 in the full process of neural tube closure along the complete body axis. Our work points to Med12 being an essential coregulator of transcription factors controlling neural tube closure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20589884     DOI: 10.1002/bdra.20693

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  8 in total

Review 1.  REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions.

Authors:  Irfan A Qureshi; Solen Gokhan; Mark F Mehler
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

2.  Eph and Ephrin Variants in Malaysian Neural Tube Defect Families.

Authors:  Siti Waheeda Mohd-Zin; Amelia Cheng Wei Tan; Wahib M Atroosh; Meow-Keong Thong; Abu Bakar Azizi; Nicholas D E Greene; Noraishah Mydin Abdul-Aziz
Journal:  Genes (Basel)       Date:  2022-05-26       Impact factor: 4.141

3.  Geminin loss causes neural tube defects through disrupted progenitor specification and neuronal differentiation.

Authors:  Ethan S Patterson; Laura E Waller; Kristen L Kroll
Journal:  Dev Biol       Date:  2014-07-01       Impact factor: 3.582

4.  MED12 regulates a transcriptional network of calcium-handling genes in the heart.

Authors:  Kedryn K Baskin; Catherine A Makarewich; Susan M DeLeon; Wenduo Ye; Beibei Chen; Nadine Beetz; Heinrich Schrewe; Rhonda Bassel-Duby; Eric N Olson
Journal:  JCI Insight       Date:  2017-07-20

5.  Glial-Specific Deletion of Med12 Results in Rapid Hearing Loss via Degradation of the Stria Vascularis.

Authors:  Teng-Wei Huang; Amrita A Iyer; Jeanne M Manalo; Junsung Woo; Navish A Bosquez Huerta; Melissa M McGovern; Heinrich Schrewe; Fredrick A Pereira; Andrew K Groves; Kevin K Ohlemiller; Benjamin Deneen
Journal:  J Neurosci       Date:  2021-07-12       Impact factor: 6.167

6.  Somatic and de novo Germline Variants of MEDs in Human Neural Tube Defects.

Authors:  Tian Tian; Xuanye Cao; Yongyan Chen; Lei Jin; Zhiwen Li; Xiao Han; Ying Lin; Bogdan J Wlodarczyk; Richard H Finnell; Zhengwei Yuan; Linlin Wang; Aiguo Ren; Yunping Lei
Journal:  Front Cell Dev Biol       Date:  2021-03-04

7.  A novel nonsense variant in MED12 associated with malformations in a female fetus.

Authors:  Soren Lejsted Faergeman; Naja Becher; Lotte Andreasen; Marianne Christiansen; Lise Frost; Ida Vogel
Journal:  Clin Case Rep       Date:  2021-12-22

Review 8.  Spina Bifida: A Review of the Genetics, Pathophysiology and Emerging Cellular Therapies.

Authors:  Abd-Elrahman Said Hassan; Yimeng Lina Du; Su Yeon Lee; Aijun Wang; Diana Lee Farmer
Journal:  J Dev Biol       Date:  2022-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.